HXN-1001 / Earendil Labs - LARVOL DELTA

Earendil Labs…announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life extended anti-TL1A antibody, in patients with ulcerative colitis, as well as enrollment completion in the Phase I trial of the antibody in healthy volunteers carried out in Australia (PRNewswire) - "The Phase IIa trial is a randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HXN-1001 in ulcerative colitis patients....In the Phase I study in healthy volunteers, HXN-1001 in single doses up to 1200 mg and multiple doses of 450 mg was well tolerated with a favorable safety profile. The antibody showed a half-life of about 8 weeks when dosed in the projected therapeutic dose range, with low incidence of anti-drug antibody response."

P1 data • Trial status • Ulcerative Colitis

Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody (The Manila Times) - "Earendil Labs...announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HXN-1001 in healthy volunteers."

New P1 trial • Inflammatory Bowel Disease